Summary
Johnson & Johnson's (JNJ) 2018 10-K filing reveals a solid financial performance driven by strong growth in its Pharmaceutical segment, which benefited from key product launches and expanded indications. The Medical Devices segment showed modest growth, while the Consumer segment experienced a slight increase, impacted by divestitures and brand performance. The company's overall sales increased by 6.7% to $81.6 billion, with pharmaceuticals being the primary growth engine. JNJ continued its commitment to innovation, investing heavily in research and development across all segments. The company also actively managed its portfolio through strategic acquisitions and divestitures, including the significant acquisition of Actelion Ltd. in the pharmaceutical segment and the divestiture of its LifeScan diabetes care business. Despite facing ongoing litigation and regulatory scrutiny, particularly in product liability, JNJ maintained effective internal controls and demonstrated a strong commitment to shareholder returns through consistent dividend payments and share repurchases.
Financial Highlights
53 data points| Revenue | $81.58B |
| Cost of Revenue | $27.09B |
| Gross Profit | $54.49B |
| SG&A Expenses | $22.54B |
| Interest Expense | $1.00B |
| Net Income | $15.30B |
| EPS (Basic) | $5.70 |
| EPS (Diluted) | $5.61 |
| Shares Outstanding (Basic) | 2.68B |
| Shares Outstanding (Diluted) | 2.73B |
Key Highlights
- 1Total sales reached $81.6 billion, a 6.7% increase year-over-year, driven by robust performance in the Pharmaceutical segment.
- 2The Pharmaceutical segment grew by 12.4%, with significant contributions from Immunology (driven by STELARA® and TREMFYA®) and Oncology (driven by DARZALEX® and IMBRUVICA®).
- 3The Medical Devices segment reported a 1.5% increase in sales, with growth in Surgery and Vision, partially offset by declines in Orthopaedics and Diabetes Care (due to divestiture).
- 4The Consumer segment saw a 1.8% increase in sales, with Beauty and OTC franchises showing strength, while Baby Care experienced a decline.
- 5Johnson & Johnson invested $10.8 billion in research and development, underscoring its commitment to innovation and pipeline advancement.
- 6The company completed significant portfolio management activities, including the acquisition of Actelion Ltd. and the divestiture of the LifeScan diabetes care business.
- 7JNJ repurchased $5.9 billion of its common stock during the year and increased its dividend for the 56th consecutive year.